Curium wraps up patient enrollment in ECLIPSE trial in prostate cancer
Curium, a leading figure in the global nuclear medicine sector, has proudly announced the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. This significant accomplishment represents a major leap forward in the quest to treat metastatic castration-resistant prostate cancer. ECLIPSE Trial: A Study in Progress The ECLIPSE trial, a Phase 3, […]